Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Venture
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

bioMmune Technologies Inc

+ Add to Watchlist

IMU:CN

0.2100 CAD 0.0100 4.55%

As of 14:53:05 ET on 05/21/2015.

Snapshot for bioMmune Technologies Inc (IMU)

Open: 0.2200 Day's Range: 0.2100 - 0.2300 Volume: 57,350
Previous Close: 0.2200 52wk Range: 0.1500 - 0.3650 1-Yr Rtn: -4.55%

Stock Chart for IMU

No chart data available.
  • IMU:CN 0.2100
  • 1D
  • 1M
  • 1Y
0.2200
Interactive IMU Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for IMU

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPTSX -
Earnings Per Share (ttm) -0.0400
Est. EPS -
Est. PEG Ratio -
Market Cap (M CAD) 5.18
Shares Outstanding (M) 24.67
30 Day Average Volume 46,089
Price/Book (mrq) 4.3891
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for IMU

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for IMU

bioMmune Technologies Inc is a private British Columbia company that was formed to commercially exploit a number of patents and patent applications that surround three technologies for the treatment of cancer. The first technology involves the discovery of HDACi's (Histone Deacetylase), The second technology deals with Calcium Channels, and the third technology is called CD74.

Robin B Hutchison "Rob"ChairmanReinhard GabathulerPresident/CEO
Judi DallingCFO/Secretary
More Company Profile & Key Executives for IMU

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil